Malvidin attenuates trauma‐induced heterotopic ossification of tendon in rats by targeting Rheb for degradation via the ubiquitin‐proteasome pathway

Abstract

AbstractThe pathogenesis of trauma‐induced heterotopic ossification (HO) in the tendon remains unclear, posing a challenging hurdle in treatment. Recognizing inflammation as the root cause of HO, anti‐inflammatory agents hold promise for its management. Malvidin (MA), possessing anti‐inflammatory properties, emerges as a potential agent to impede HO progression. This study aimed to investigate the effect of MA in treating trauma‐induced HO and unravel its underlying mechanisms. Herein, the effectiveness of MA in preventing HO formation was assessed through local injection in a rat model. The potential mechanism underlying MA's treatment was investigated in the tendon‐resident progenitor cells of tendon‐derived stem cells (TDSCs), exploring its pathway in HO formation. The findings demonstrated that MA effectively hindered the osteogenic differentiation of TDSCs by inhibiting the mTORC1 signalling pathway, consequently impeding the progression of trauma‐induced HO of Achilles tendon in rats. Specifically, MA facilitated the degradation of Rheb through the K48‐linked ubiquitination‐proteasome pathway by modulating USP4 and intercepted the interaction between Rheb and the mTORC1 complex, thus inhibiting the mTORC1 signalling pathway. Hence, MA presents itself as a promising candidate for treating trauma‐induced HO in the Achilles tendon, acting by targeting Rheb for degradation through the ubiquitin‐proteasome pathway.